Kestra Medical Technologies, Ltd. $KMTS Position Increased by Eventide Asset Management LLC

Eventide Asset Management LLC grew its position in Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) by 285.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,060,557 shares of the company’s stock after buying an additional 785,557 shares during the quarter. Eventide Asset Management LLC owned approximately 2.07% of Kestra Medical Technologies worth $17,584,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the company. Quarry LP acquired a new position in Kestra Medical Technologies in the 1st quarter worth approximately $33,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Kestra Medical Technologies in the second quarter worth $54,000. New York State Common Retirement Fund purchased a new position in shares of Kestra Medical Technologies during the second quarter valued at $93,000. Walleye Capital LLC acquired a new position in Kestra Medical Technologies during the second quarter valued at $166,000. Finally, Rhumbline Advisers purchased a new stake in Kestra Medical Technologies in the 2nd quarter worth about $200,000.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on KMTS shares. The Goldman Sachs Group reiterated a “neutral” rating and issued a $25.00 target price on shares of Kestra Medical Technologies in a report on Saturday. Wall Street Zen downgraded shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research report on Sunday, September 28th. Piper Sandler increased their target price on shares of Kestra Medical Technologies from $27.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday. Wells Fargo & Company boosted their price target on shares of Kestra Medical Technologies from $27.00 to $28.00 and gave the company an “overweight” rating in a report on Friday. Finally, BTIG Research started coverage on shares of Kestra Medical Technologies in a research note on Tuesday, November 18th. They issued a “buy” rating and a $32.00 price target on the stock. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.14.

Kestra Medical Technologies Stock Performance

Shares of KMTS opened at $26.17 on Friday. The firm has a market cap of $1.35 billion and a price-to-earnings ratio of -10.26. The company’s fifty day moving average is $25.54 and its 200-day moving average is $20.81. The company has a quick ratio of 6.84, a current ratio of 6.84 and a debt-to-equity ratio of 0.23. Kestra Medical Technologies, Ltd. has a 12 month low of $13.25 and a 12 month high of $30.00.

Kestra Medical Technologies (NASDAQ:KMTS) last released its quarterly earnings data on Thursday, September 11th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.66) by $0.16. The business had revenue of $19.37 million during the quarter, compared to analyst estimates of $17.68 million.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.